Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts
Open Access
- 21 December 2012
- journal article
- review article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 15 (2), 189-197
- https://doi.org/10.1093/neuonc/nos305
Abstract
Liposomal drug packaging is well established as an effective means for increasing drug half-life, sustaining drug activity, and increasing drug efficacy, whether administered locally or distally to the site of disease. However, information regarding the relative effectiveness of peripheral (distal) versus local administration of liposomal therapeutics is limited. This issue is of importance with respect to the treatment of central nervous system cancer, for which the blood-brain barrier presents a significant challenge in achieving sufficient drug concentration in tumors to provide treatment benefit for patients. We compared the anti-tumor activity and efficacy of a nanoliposomal formulation of irinotecan when delivered peripherally by vascular route with intratumoral administration by convection-enhanced delivery (CED) for treating intracranial glioblastoma xenografts in athymic mice. Our results show significantly greater anti-tumor activity and survival benefit from CED of nanoliposomal irinotecan. In 2 of 3 efficacy experiments, there were animal subjects that experienced apparent cure of tumor from local administration of therapy, as indicated by a lack of detectable intracranial tumor through bioluminescence imaging and histopathologic analysis. Results from investigating the effectiveness of combination therapy with nanoliposomal irinotecan plus radiation revealed that CED administration of irinotecan plus radiation conferred greater survival benefit than did irinotecan or radiation monotherapy and also when compared with radiation plus vascularly administered irinotecan. Our results indicate that liposomal formulation plus direct intratumoral administration of therapeutic are important for maximizing the anti-tumor effects of irinotecan and support clinical trial evaluation of this therapeutic plus route of administration combination.This publication has 26 references indexed in Scilit:
- Challenges in drug delivery to tumors of the central nervous system: An overview of pharmacological and surgical considerationsAdvanced Drug Delivery Reviews, 2012
- Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenograftsNeuro-Oncology, 2007
- Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts1Neuro-Oncology, 2007
- Blood–brain barrier and chemotherapeutic treatment of brain tumorsExpert Review of Neurotherapeutics, 2006
- Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model1Neuro-Oncology, 2006
- Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiformeNeuro-Oncology, 2005
- Extensive Distribution of Liposomes in Rodent Brains and Brain Tumors Following Convection-Enhanced DeliveryJournal of Neuro-Oncology, 2004
- Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFRGenes, Chromosomes and Cancer, 2003
- Liposome-mediated therapy of intracranial brain tumors in a rat model.Pharmaceutical Research, 1997
- Convection-enhanced delivery of macromolecules in the brain.Proceedings of the National Academy of Sciences of the United States of America, 1994